

Prescribing Information: Aldurazyme (Iaronidase) 100 U/ml concentrate for solution for infusion
Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Presentation: 1ml contains 100U (approximately 0.58mg) of Iaronidase. Each vial of 5ml contains 500U of Iaronidase and 1.29mmol sodium

Indication: Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis I (MPS I; α -L-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

Dosage and administration: Aldurazyme treatment should be supervised by a physician experienced in the management of patients with MPS I or other inherited metabolic diseases. Administration of Aldurazyme should be carried out in an appropriate clinical setting where resuscitation equipment to manage medical emergencies would be readily available. The recommended dosage regimen of Aldurazyme is 100U/kg bodyweight administered once every week as an intravenous (IV) infusion. The initial infusion rate of 2U/kg/h may be incrementally increased every 15 minutes, if tolerated, to a maximum of 43U/kg/h. The total volume of the administration should be delivered in approximately 3-4 hours. **Paediatric:** No dose adjustment necessary. **Elderly (≥ 65 years):** No data therefore no dosage can be recommended. **Renal and hepatic impairment:** No data therefore no dosage can be recommended.

Contraindications: Severe Hypersensitivity (e.g. anaphylactic reaction) to the active substance or to any of the excipients.

Warnings and Precautions: **Traceability:** In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. **Hypersensitivity reactions (including anaphylaxis):** Some of these reactions were life threatening and included respiratory failure/distress, stridor, obstructive airways disorder, hypoxia, hypotension, bradycardia, and urticaria. Appropriate medical support measures, including cardiopulmonary resuscitation equipment should be readily available when Aldurazyme is administered. If anaphylaxis or other severe hypersensitivity reactions occur, the infusion of Aldurazyme should be discontinued immediately. Caution should be exercised if epinephrine is being considered for use in patients with MPS I due to the increased prevalence of coronary artery disease in these patients. In patients with severe hypersensitivity, desensitization procedure to Aldurazyme may be considered. If the decision is made to re-administer the product, extreme care should be exercised, with appropriate resuscitation measures available. If mild or moderate hypersensitivity reactions occur, the infusion rate may be slowed or temporarily stopped. Once a patient tolerates the infusion, the dose may be increased to reach the approved dose. **Infusion-associated reactions (IARs):** Patients with an acute underlying illness at the time of Aldurazyme infusion appear to be at greater risk for IARs. Careful consideration should be given to the patient's clinical status prior to administration of Aldurazyme. Initial administration of Aldurazyme or upon re-administration (following interruption of treatment) it is recommended that patients be administered pre-treatment medication (antihistamines and/or antipyretics) approximately 60 minutes prior to the infusion, to minimise the potential occurrence of IARs. If clinically indicated, administration of pre-treatment medication with subsequent infusions of Aldurazyme should be considered. As there is little experience on resumption of treatment following prolonged interruption, use caution due to the theoretical increased risk of hypersensitivity reaction after treatment interruption. Severe IARs have been reported in patients with pre-existing severe underlying upper airway involvement and

therefore specifically these patients should continue to be closely monitored and only be infused with Aldurazyme in an appropriate clinical setting where resuscitation equipment to manage medical emergencies would be readily available. In case of a single severe IAR, the infusion should be stopped until the symptoms have resolved, and symptomatic treatment (e.g. with antihistamines and antipyretics/anti-inflammatories) should be considered. The benefits and risk of re-administering Aldurazyme following severe IARs should be considered. The infusion can be restarted with a reduction of the infusion rate to 1/2–1/4 the rate of the infusion at which the reaction occurred. In case of a recurrent moderate IAR or re-challenge after a single severe IAR, pre-treatment should be considered (antihistamines and antipyretics/anti-inflammatories and/or corticosteroids) and a reduction of the infusion rate to 1/2–1/4 the rate of the infusion at which the previous reaction occurred. In case of a mild or moderate IAR, symptomatic treatment (e.g. with antihistamines and antipyretics/anti-inflammatories) should be considered and/or a reduction in the infusion rate to half the infusion rate at which the reaction occurred. Once a patient tolerates the infusion, the dose may be increased to reach the approved dose. **Immunogenicity:** Based on the randomised, double-blind, placebo-controlled Phase 3 clinical trial, almost all patients are expected to develop IgG antibodies to Iaronidase, mostly within 3 months of initiation of treatment. Severe allergic-type hypersensitivity reactions are possible. IARs and hypersensitivity reactions may occur independently of the development of anti-drug antibodies (ADAs). Patients who have developed antibodies or symptoms of IARs should be treated with caution when administering Aldurazyme. Patients treated with Aldurazyme should be closely monitored and all cases of infusion-associated reactions, delayed reactions and possible immunological reactions reported. Antibody status, including IgG, IgE, neutralizing antibodies for enzyme activity or enzyme reuptake, should be regularly monitored and reported. In clinical studies IARs were usually manageable by slowing the rate of infusion and by (pre-) treating the patient with antihistamines and/or antipyretics (paracetamol or ibuprofen), thus enabling the patient to continue treatment. **Sodium:** This medicinal product contains 30 mg sodium per vial, equivalent to 1.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult and is administered in 0.9% sodium chloride intravenous solution. **Interactions:** No interaction studies have been performed. Aldurazyme is an unlikely candidate for cytochrome P450 mediated interactions. Aldurazyme should not be administered simultaneously with chloroquine or procaine due to a potential risk of interference with the intracellular uptake of Aldurazyme. **Pregnancy:** There are inadequate data on the use of Aldurazyme in pregnant women, thus the potential risk for humans is unknown. Aldurazyme should not be used in pregnancy unless clearly necessary. **Breastfeeding:** Aldurazyme may be excreted in milk. It is recommended to stop breast-feeding during Aldurazyme treatment. **Fertility:** no clinical data.

Adverse reactions: **Very common ($\geq 1/10$):** Headache, flushing, nausea, abdominal pain, rash, arthropathy, arthralgia, back pain, pain in the extremity, pyrexia, infusion site reactions*. **Common ($\geq 1/100$ to $< 1/10$):** Anaphylactic reaction, restlessness, paraesthesia, dizziness, tachycardia, hypotension, pallor, peripheral coldness, respiratory distress, dyspnoea, cough, vomiting, diarrhoea, angio oedema, swelling face, urticaria, pruritis, cold sweat, alopecia, hyperhidrosis,

musculoskeletal pain, chills, feeling cold, feeling hot, fatigue, influenza-like illness, injection site pain, body temperature increased, oxygen saturation decreased. Unknown: Hypersensitivity, bradycardia, hypertension, cyanosis, hypoxia, tachypnoea, bronchospasm, respiratory arrest, laryngeal oedema, respiratory failure, pharyngeal swelling, stridor, obstructive airways disorder, lip swelling, swollen tongue, erythema, facial oedema, extravasation, oedema peripheral, drug specific antibody, neutralising antibodies and blood pressure increased. * During clinical trials and post-marketing experience, infusion/injection site reactions notably included: swelling, erythema, oedema, discomfort, urticaria, pallor, macule, and warmth. Please refer to the SmPC for further information.

Legal category: POM. **List Price:** *NI*: £444.70. **IE:** Price on application, **Marketing authorisation holder:** Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands. **Marketing authorisation number:** EU/1/03/253/001-003. **Further information available from:** *NI*: Medical Information, Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. uk-medicalinformation@sanofi.com. **IE:** Sanofi, 18 Riverwalk, Citywest Business Campus, Dublin 24, or contact IEmedinfo@sanofi.com. **SmPC date:** 02 May 2023.

Date of Preparation: May 2023.

Document number: MAT-IE-2300242(v1.0)

Adverse events should be reported.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314.

Alternatively, send via email to UK-drugsafety@sanofi.com

In Ireland: www.hpra.ie; email: medsafety@hpra.ie

Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600.

Alternatively, send via email to IEPharmacovigilance@sanofi.com